CSPC Innovation Pharmaceutical Co Ltd Class A
CSPC Innovation Pharmaceutical Co., Ltd. engages in the research and development, production, and sales of biopharmaceuticals, functional foods, and raw materials in China and internationally. It offers functional raw ingredients, including caffeine, acarbose, anhydrous glucose, theophylline, aminophylline, dihydroxyphylline, theobromine, pentoxifylline, doxofylline, and biological enzymes; and h… Read more
CSPC Innovation Pharmaceutical Co Ltd Class A (300765) - Net Assets
Latest net assets as of September 2025: CN¥4.16 Billion CNY
Based on the latest financial reports, CSPC Innovation Pharmaceutical Co Ltd Class A (300765) has net assets worth CN¥4.16 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥6.21 Billion) and total liabilities (CN¥2.05 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥4.16 Billion |
| % of Total Assets | 67.06% |
| Annual Growth Rate | 23.67% |
| 5-Year Change | 67.33% |
| 10-Year Change | 617.25% |
| Growth Volatility | 40.79 |
CSPC Innovation Pharmaceutical Co Ltd Class A - Net Assets Trend (2014–2024)
This chart illustrates how CSPC Innovation Pharmaceutical Co Ltd Class A's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for CSPC Innovation Pharmaceutical Co Ltd Class A (2014–2024)
The table below shows the annual net assets of CSPC Innovation Pharmaceutical Co Ltd Class A from 2014 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥4.50 Billion | -11.62% |
| 2023-12-31 | CN¥5.09 Billion | +28.98% |
| 2022-12-31 | CN¥3.94 Billion | +33.23% |
| 2021-12-31 | CN¥2.96 Billion | +10.18% |
| 2020-12-31 | CN¥2.69 Billion | +11.24% |
| 2019-12-31 | CN¥2.42 Billion | +141.69% |
| 2018-12-31 | CN¥999.35 Million | +30.31% |
| 2017-12-31 | CN¥766.93 Million | +34.07% |
| 2016-12-31 | CN¥572.02 Million | -8.74% |
| 2015-12-31 | CN¥626.83 Million | +16.69% |
| 2014-12-31 | CN¥537.16 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to CSPC Innovation Pharmaceutical Co Ltd Class A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 613.4% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥1.33 Billion | 35.60% |
| Common Stock | CN¥1.40 Billion | 37.65% |
| Other Comprehensive Income | CN¥342.61 Million | 9.18% |
| Other Components | CN¥655.34 Million | 17.57% |
| Total Equity | CN¥3.73 Billion | 100.00% |
CSPC Innovation Pharmaceutical Co Ltd Class A Competitors by Market Cap
The table below lists competitors of CSPC Innovation Pharmaceutical Co Ltd Class A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Innoviva Inc
NASDAQ:INVA
|
$1.53 Billion |
|
Co-Tech Development
TWO:8358
|
$1.53 Billion |
|
ISA ENERGIA BRASIL
SA:ISAE3
|
$1.53 Billion |
|
Landis+Gyr Group AG
OTCGREY:LGYRF
|
$1.53 Billion |
|
XiaMen HongXin Electron-tech Co Ltd
SHE:300657
|
$1.53 Billion |
|
Veris Residential Inc
NYSE:VRE
|
$1.53 Billion |
|
Transcend Information Inc
TW:2451
|
$1.53 Billion |
|
Orora Ltd
AU:ORA
|
$1.53 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in CSPC Innovation Pharmaceutical Co Ltd Class A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 5,078,808,635 to 3,730,544,275, a change of -1,348,264,360 (-26.5%).
- Net income of 53,726,319 contributed positively to equity growth.
- Dividend payments of 374,161,265 reduced retained earnings.
- Share repurchases of 316,780,504 reduced equity.
- Other comprehensive income increased equity by 56,840,180.
- Other factors decreased equity by 767,889,090.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥53.73 Million | +1.44% |
| Dividends Paid | CN¥374.16 Million | -10.03% |
| Share Repurchases | CN¥316.78 Million | -8.49% |
| Other Comprehensive Income | CN¥56.84 Million | +1.52% |
| Other Changes | CN¥-767.89 Million | -20.58% |
| Total Change | CN¥- | -26.55% |
Book Value vs Market Value Analysis
This analysis compares CSPC Innovation Pharmaceutical Co Ltd Class A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 12.13x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 53.30x to 12.13x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | CN¥0.61 | CN¥32.35 | x |
| 2015-12-31 | CN¥0.71 | CN¥32.35 | x |
| 2016-12-31 | CN¥0.78 | CN¥32.35 | x |
| 2017-12-31 | CN¥1.04 | CN¥32.35 | x |
| 2018-12-31 | CN¥1.34 | CN¥32.35 | x |
| 2019-12-31 | CN¥2.45 | CN¥32.35 | x |
| 2020-12-31 | CN¥2.72 | CN¥32.35 | x |
| 2021-12-31 | CN¥3.00 | CN¥32.35 | x |
| 2022-12-31 | CN¥3.53 | CN¥32.35 | x |
| 2023-12-31 | CN¥4.34 | CN¥32.35 | x |
| 2024-12-31 | CN¥2.67 | CN¥32.35 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently CSPC Innovation Pharmaceutical Co Ltd Class A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 1.44%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 2.71%
- • Asset Turnover: 0.33x
- • Equity Multiplier: 1.61x
- Recent ROE (1.44%) is below the historical average (17.01%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 20.15% | 16.63% | 0.78x | 1.55x | CN¥54.52 Million |
| 2015 | 18.50% | 15.58% | 0.78x | 1.53x | CN¥53.10 Million |
| 2016 | 36.11% | 23.20% | 0.92x | 1.69x | CN¥149.38 Million |
| 2017 | 25.41% | 18.90% | 0.91x | 1.47x | CN¥118.22 Million |
| 2018 | 22.59% | 18.05% | 0.89x | 1.40x | CN¥124.76 Million |
| 2019 | 11.35% | 21.74% | 0.44x | 1.19x | CN¥32.56 Million |
| 2020 | 11.20% | 22.76% | 0.45x | 1.10x | CN¥32.02 Million |
| 2021 | 13.32% | 21.26% | 0.57x | 1.09x | CN¥98.02 Million |
| 2022 | 18.45% | 27.65% | 0.57x | 1.16x | CN¥332.72 Million |
| 2023 | 8.55% | 17.11% | 0.45x | 1.11x | CN¥-73.45 Million |
| 2024 | 1.44% | 2.71% | 0.33x | 1.61x | CN¥-319.33 Million |
Industry Comparison
This section compares CSPC Innovation Pharmaceutical Co Ltd Class A's net assets metrics with peer companies in the Packaged Foods industry.
Industry Context
- Industry: Packaged Foods
- Average net assets among peers: $2,496,572,190
- Average return on equity (ROE) among peers: -3.76%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| CSPC Innovation Pharmaceutical Co Ltd Class A (300765) | CN¥4.16 Billion | 20.15% | 0.49x | $1.53 Billion |
| Xiwang Foodstuffs Co Ltd (000639) | $65.61 Million | -62.17% | 1.91x | $345.26 Million |
| Nanfang Black Sesame Group Co Ltd (000716) | $199.49 Million | -32.62% | 2.81x | $346.21 Million |
| CNFC Overseas Fishery Co Ltd (000798) | $727.64 Million | 8.49% | 0.27x | $430.25 Million |
| Henan Shuanghui Investment & Development Co Ltd (000895) | $16.36 Billion | 24.69% | 0.34x | $3.98 Billion |
| Xinjiang Chalkis Co Ltd (000972) | $760.28 Million | -33.42% | 2.17x | $202.97 Million |
| Zhengzhou Qianweiyangchu Food Co Ltd (001215) | $332.95 Million | 17.62% | 0.88x | $266.09 Million |
| Wenzhou Yuanfei Pet Toy Products Co. Ltd. A (001222) | $1.35 Billion | 9.31% | 0.15x | $160.97 Million |
| Guangdong Yuehai Feeds Group Co.Ltd. (001313) | $2.07 Billion | 7.87% | 0.47x | $169.20 Million |
| Shandong Oriental Ocean Sci-Tech Co Ltd (002086) | $393.72 Million | 8.08% | 0.70x | $460.31 Million |
| Xinjiang Tecon Animal Husbandry Bio-Technology Co Ltd (002100) | $2.70 Billion | 14.52% | 0.66x | $903.18 Million |